Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

45 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Leveraging the holistic benefits of biosimilars in Europe - part 2: how payers can safeguard the future of a healthy biosimilar market environment.
Mestre-Ferrandiz J, Czech M, Smolen JS, Cornes P, Aapro MS, Danese S, Deitch S, Tyldsley H, Foster W, Shah P, Latymer M, Vulto AG. Mestre-Ferrandiz J, et al. Expert Rev Pharmacoecon Outcomes Res. 2024 Apr;24(4):509-519. doi: 10.1080/14737167.2024.2310684. Epub 2024 Feb 12. Expert Rev Pharmacoecon Outcomes Res. 2024. PMID: 38284223
Evaluation of antibody-based preventive alternatives for respiratory syncytial virus: a novel multi-criteria decision analysis framework and assessment of nirsevimab in Spain.
Mestre-Ferrándiz J, Rivero A, Orrico-Sánchez A, Hidalgo Á, Abdalla F, Martín I, Álvarez J, García-Cenoz M, Del Carmen Pacheco M, Garcés-Sánchez M, Zozaya N, Ortiz-de-Lejarazu R. Mestre-Ferrándiz J, et al. BMC Infect Dis. 2024 Jan 18;24(1):99. doi: 10.1186/s12879-024-08988-9. BMC Infect Dis. 2024. PMID: 38238680 Free PMC article.
A Review of Current Approaches to Evaluating and Reimbursing New Medicines in a Subset of OECD Countries.
Zozaya N, Villaseca J, Fernández I, Abdalla F, Cadenas-Noreña B, Calleja MÁ, Gómez-Pajuelo P, Mestre-Ferrándiz J, Oliva-Moreno J, Trillo JL, Hidalgo-Vega Á. Zozaya N, et al. Among authors: mestre ferrandiz j. Appl Health Econ Health Policy. 2024 May;22(3):297-313. doi: 10.1007/s40258-023-00867-9. Epub 2024 Jan 12. Appl Health Econ Health Policy. 2024. PMID: 38214848 Review.
Expert-based collaborative analysis of the situation and prospects of biomarker test implementation in oncology in Spain.
Mestre-Ferrándiz J, Franch Camino B, Hidalgo Á, Del Llano Núñez-Cortés A, Del Llano Señarís JE, Lumbreras B, Beas Pedraza D, Nuño-Solinís R, Paz-Ares L, Ramón Y Cajal S, Rodríguez MJ. Mestre-Ferrándiz J, et al. Clin Transl Oncol. 2024 Apr;26(4):985-990. doi: 10.1007/s12094-023-03338-8. Epub 2024 Jan 11. Clin Transl Oncol. 2024. PMID: 38206517 Free PMC article.
Capturing the holistic value of biosimilars in Europe - part 1: a historical perspective.
Mestre-Ferrandiz J, Czech M, Smolen JS, Cornes P, Aapro MS, Danese S, Deitch S, Tyldsley H, Foster W, Shah P, Latymer M, Vulto AG. Mestre-Ferrandiz J, et al. Expert Rev Pharmacoecon Outcomes Res. 2024 Feb;24(2):237-250. doi: 10.1080/14737167.2023.2297926. Epub 2024 Jan 25. Expert Rev Pharmacoecon Outcomes Res. 2024. PMID: 38175140
Review and Assessment of Policy Options for Improving Access to Combination Therapies in Oncology in Europe.
Henshall CH, Dankó D, Barham L, Espín J, Felix J, Harney M, Indra P, Mestre-Ferrandiz J, de Pouvourville G, Spandonaro F, Vončina L, Wilking N. Henshall CH, et al. Among authors: mestre ferrandiz j. Appl Health Econ Health Policy. 2023 Jul;21(4):537-546. doi: 10.1007/s40258-023-00795-8. Epub 2023 Mar 10. Appl Health Econ Health Policy. 2023. PMID: 36897550 Review.
45 results